Journal article
The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence
Abstract
OBJECTIVE: To review and summarize the literature concerning the cost-effectiveness of palivizumab compared to no prophylaxis in infants and young children with congenital heart disease (CHD).
METHODS: A systematic literature search (MEDLINE to March 2012, limited to English language) identified studies that examined the cost-effectiveness of palivizumab in CHD populations. The quality of each study was assigned a quality score of 1-100 based …
Authors
Hussman JM; Lanctôt KL; Paes B
Journal
Journal of Medical Economics, Vol. 16, No. 1, pp. 115–124
Publisher
Taylor & Francis
Publication Date
2 2013
DOI
10.3111/13696998.2012.734886
ISSN
1369-6998